Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

NCT01207765 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped changes in practice

Conditions

Multiple Myeloma

Interventions

DRUG: indium-111-ibritumomab tiuxetan
DRUG: 90Y Zevalin

Sponsor

Tufts Medical Center

Collaborators

[object Object]